Biologics Contract Development Market Report: Trends, Forecast and Competitive Analysis to 2030

Biologics Contract Development Trends and Forecast

The future of the global biologics contract development market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorder, and hematological disorder markets. The global biologics contract development market is expected to reach an estimated $40.9 billion by 2030 with a CAGR of 11.5% from 2024 to 2030. The major drivers for this market are rising number of drug development procedures by pharmaceutical companies, growing adoption of advanced technologies, and favorable environment for clinical trials in the developing countries.

A more than 150-page report is developed to help in your business decisions.

Biologics Contract Development by Segment

The study includes a forecast for the global biologics contract development by source, product service, disease indication, and region.

Biologics Contract Development Market by Source [Shipment Analysis by Value from 2018 to 2030]:

• Microbial
• Mammalian
• Others

Biologics Contract Development Market by Product Service [Shipment Analysis by Value from 2018 to 2030]:

• Cell Line Development
• Process Development
• Others

Biologics Contract Development Market by Disease Indication [Shipment Analysis by Value from 2018 to 2030]:

• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

Biologics Contract Development Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Biologics Contract Development Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biologics contract development companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biologics contract development companies profiled in this report include-

• WuXi Biologics
• Abzena
• Fujifilm Diosynth Biotechnologies
• KBI Biopharma
• AGC Biologics
• Thermo Fisher Scientific
• Curia Global
• Genscript
• Bionova Scientific
• BioXcellence

Biologics Contract Development Market Insights

Lucintel forecasts that mammalian will remain the larger segment over the forecast period due to increasing adoption of mammalian cells for protein expression, which provides a major advantage by developing mammalian proteins with correct post-translational modifications that delivers a native structure.

Within this market, oncology will remain the largest segment due to growing demand for therapy, which encourages more investments in research and development and outsourcing.

North America will remain the largest region over the forecast period due to growing R&D investments, rising demand of clinical trials, and presence of major players in the region.

Features of the Global Biologics Contract Development Market

Market Size Estimates: Biologics contract development market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Biologics contract development market size by source, product service, disease indication, and region in terms of value ($B).

Regional Analysis: Biologics contract development market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different sources, product services, disease indication, and regions for the biologics contract development market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biologics contract development market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the biologics contract development market size?

Answer: The global biologics contract development market is expected to reach an estimated $40.9 billion by 2030.

Q2. What is the growth forecast for biologics contract development market?

Answer: The global biologics contract development market is expected to grow with a CAGR of 11.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the biologics contract development market?

Answer: The major drivers for this market are rising number of drug development procedures by pharmaceutical companies, growing adoption of advanced technologies, and favorable environment for clinical trials in the developing countries.

Q4. What are the major segments for biologics contract development market?

Answer: The future of the biologics contract development market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorder, and hematological disorder markets.

Q5. Who are the key biologics contract development market companies?

Answer: Some of the key biologics contract development companies are as follows:

• WuXi Biologics
• Abzena
• Fujifilm Diosynth Biotechnologies
• KBI Biopharma
• AGC Biologics
• Thermo Fisher Scientific
• Curia Global
• Genscript
• Bionova Scientific
• BioXcellence

Q6. Which biologics contract development market segment will be the largest in future?

Answer: Lucintel forecasts that mammalian will remain the larger segment over the forecast period due to increasing adoption of mammalian cells for protein expression, which provides a major advantage by developing mammalian proteins with correct post-translational modifications that delivers a native structure.

Q7. In biologics contract development market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing R&D investments, rising demand of clinical trials, and presence of major players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the biologics contract development market by source (microbial, mammalian, and others), product service (cell line development, process development, and others), disease indication (oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?